Aziltry CH Tablet contains Azilsartan Medoxomil 40 mg and Chlorthalidone 12.5 mg, a combination formulation used for the management of hypertension and improved cardiovascular health. It helps reduce elevated blood pressure by combining the action of an angiotensin receptor blocker with a diuretic agent. The formulation supports better blood pressure control by relaxing blood vessels and helping the body remove excess fluid, thereby reducing the workload on the heart.
Azilsartan Medoxomil works by blocking the action of angiotensin II, a substance that causes blood vessels to narrow and increases blood pressure. By preventing this effect, it helps blood vessels relax and improves circulation. Chlorthalidone acts as a thiazide-like diuretic that promotes the removal of excess sodium and water from the body, contributing to effective blood pressure reduction and improved fluid balance.
The tablet is commonly prescribed for patients with hypertension who require combination therapy for better blood pressure management. It may be recommended when single-drug treatment does not provide adequate control or when additional cardiovascular support is needed. Consistent blood pressure management helps reduce the risk of complications such as heart disease, stroke, and kidney-related problems when used along with appropriate lifestyle measures.
With the increasing prevalence of hypertension and cardiovascular disorders, Aziltry CH Tablet maintains strong demand in the cardiology segment. Its effective dual-action composition, physician acceptance, and importance in long-term blood pressure management make it a valuable product for retailers and distributors. The product offers excellent business potential and sustainable growth opportunities within the cardiovascular pharmaceutical market.